Fibromyalgia, Depression, and the Menopausal Transition

Primary Psychiatry

Volumn 11, Issue 1, 2004, Pages 31-33

  Clayton, Anita H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE; MIRTAZAPINE; NEFAZODONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; OPIATE; S ADENOSYLMETHIONINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL FEATURE; COMORBIDITY; DEPRESSION; FEMALE; FIBROMYALGIA; HUMAN; MENOPAUSE; PATHOPHYSIOLOGY; SEROTONIN RELEASE; SHORT SURVEY; TREATMENT PLANNING;

EID: 1842507991     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172.
2. Goldenberg DL. Fibromyalgia syndrome a decade later: What have we learned? Arch Int Med. 1999;159:777-785.
3. Hassett AL, Cone JD, Patella SJ, Sigal LH. The role of catastrophizing in the pain and depression of women with fibromyalgia syndrome. Arthritis Rheum. 2000;43:2493-2500.
4. Neeck G, Crofford LJ. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am. 2000;26:989-1002.
5. Korszun A, Young EA, Engleberg NC, et al. Follicular phase hypothalamic-pituitary-gonadal axis function in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol. 2000;26:1526-1530.
6. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550-556.
7. Offenbaecher M, Bondy B, de Jonge S, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum. 1999;42:2482-2488.
8. Epstein SA, Kay G, Clauw D, et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics. 1999;1:57-63.
9. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. Psychosomatics 2000;2:104-113.
10. O'Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants. J Gen Int Med. 2000;15:659-666.
11. Goodnick PJ, Breakstone K, Kumar A, et al. Nefazodone in diabetic neuropathy: response and biology [letter]. Psychosom Med. 2000;62:599-600.
12. Dwight MM, Arnold LM, O'Brien H, et al. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics. 1998;39:14-17.
13. Clayton AH, Kaltsounis-Puckett J. Combination therapy in the treatment of major depressive disorder complicated by fibromyalgia and menopause. Psychosomatics. 2002;6:491-493.
14. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529-534.
15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;3:321-333.